medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2022, Number 4

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2022; 38 (4)

Influence of JAK2V617F allelic burden in Cuban patients with essential thrombocythemia and primary myelofibrosis

Fernández ML, Garrote SH, Amor VAM, Díaz ACA, Fernández ÁJD, Lavaut SK, González GA, Lam DRM, Quintero SY, Romero GA, Cabrera HD

Language: Spanish
References: 22
Page: 1-15
PDF size: 1120.48 Kb.


ABSTRACT

Introduction: The frequency of the JAK2V617F mutation is estimated to be between 50 % and 60 % in patients with essential thrombocythemia and primary myelofibrosis. 30 % of patients with polycythemia vera and primary myelofibrosis and 2-4 % of patients with essential thrombocythemia show loss of heterozygosity.
Objectives: To evaluate the influence of the allelic load of the JAK2V617F mutation in the diagnosis of these diseases in Cuban patients and its relationship with clinical-hematological variables.
Methodology: A retrospective, descriptive and longitudinal study was carried out at the Institute of Hematology and Immunology between 2010 and 2020. All patients with suspected essential thrombocythemia and primary myelofibrosis with valid DNA samples were included. The allelic load of the mutation was quantified by real-time PCR.
Results: The mutation was detected in 66.7 % of those diagnosed with essential thrombocythemia and primary myelofibrosis. 62.5 % of the patients with primary myelofibrosis were homozygous for the mutation, while in essential thrombocythemia only 20.8 %. The difference in mean allelic loads between both diseases was statistically significant. No significant differences were found in the comparison of clinical and hematological variables in these diseases or association with allelic load, with the exception of platelets in primary myelofibrosis.
Conclusions: The study was limited by the small sample of patients, but it corresponds to other investigations that support the concept that the phenotypic presentation of myeloproliferative neoplasms is influenced by the mutational load of JAK2V617F.


REFERENCES

  1. Komrokji R, Kuykendall A, Padron E, Verstovsek S. Myelofibrosis. En: Greer JP, Rodgers GM, Glader B, Arber DA, Means R, List AF, et al, eds. Wintrobe's clinical hematology. 14th ed. Philadelphia: Wolters Kluwer; 2019. p. 5437-68.

  2. Jang MA, Choi CW. Recent insights regarding the molecular basis of myeloproliferative neoplasms. Korean J Intern Med. 2020 Jan;35(1):1-11. DOI: https://10.3904/kjim.2019.3172.

  3. Schischlik F, Kralovics R. Mutations in myeloproliferative neoplasms - their significance and clinical use. Expert Rev Hematol. 2017 Nov;10(11):961-73. DOI: https://10.1080/17474086.2017.13805153.

  4. Greer JP, Rodgers GM, Glader B, Arber DA, Means R, List AF, et al, eds. Wintrobe's clinical hematology. 14th ed. Philadelphia: Wolters Kluwer; 2019.

  5. Sharma V, Wright KL, Epling-Burnette PK, Reuther GW. Metabolic vulnerabilities and epigenetic dysregulation in myeloproliferative neoplasms. Front Immunol. 2020 Nov;11:604142. DOI: https://10.3389/fimmu.2020.6041425.

  6. Rumi E, Cazzola M. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood. 2017 Feb;129(6):680-92. DOI: https://10.1182/blood-2016-10-6959576.

  7. Lanikova L, Babosova O, Prchal JT. Experimental modeling of myeloproliferative neoplasms. Genes (Basel). 2019 Oct;10(10):81. DOI: https://10.3390/genes10100813

  8. González MS, De Brasi CD, Bianchini M, Gargallo P, Stanganelli C, Zalcberg I, et al. Improved diagnosis of the transition to JAK2V617F homozygosity: the key feature for predicting the evolution of myeloproliferative neoplasms. PLoS One. 2014 Jan;9(1):e86401. DOI: https://10.1371/journal.pone.00864018.

  9. Kjær L. Clonal hematopoiesis and mutations of myeloproliferative neoplasms. Cancers (Basel). 2020 Jul;12(8):2100. DOI: https://10.3390/cancers120821009.

  10. Sazawal S, Singh K, Chhikara S, Chaubey R, Mahapatra M, Saxena R. Influence of JAK2V617F allele burden on clinical phenotype of polycythemia vera patients: A study from India. South Asian J Cancer. 2019 Apr-Jun; 8(2):127-9. DOI: https://10.4103/sajc.sajc_161_1810.

  11. Popova-Labachevska M, Panovska-Stavridis I, Eftimov A, KapedanovskaNestorovska A, Cevreska L, Ivanovski M, et al. Evaluation of the JAK2V617F mutational burden in patients with philadelphia chromosome Negative myeloproliferative neoplasms: A single-center experience. Balkan J Med Genet. 2019 Dec;22(2):31-36. DOI: https://10.2478/bjmg-2019-002111.

  12. Park SH, Chi HS, Cho YU, Jang S, Park CJ. The allele burden of JAK2 V617F can aid in differential diagnosis of Philadelphia Chromosome-Negative Myeloproliferative Neoplasm. Blood Res. 2013 Jun;48(2):128-32. DOI: https://10.5045/br.2013.48.2.12812.

  13. Singdong R, Siriboonpiputtana T, Chareonsirisuthigul T, Kongruang A, Limsuwanachot N, Sirirat T, et al. Characterization and Prognosis Significance of JAK2 (V617F), MPL, and CALR Mutations in Philadelphia-Negative Myeloproliferative Neoplasms. Asian Pac J Cancer Prev. 2016 Oct;17(10):4647-53. DOI: https://10.22034/apjcp.2016.17.10.464713.

  14. Azevedo AP, Silva SN, Alice Reichert A, Lima F, Júnior E, Rueff J. Prevalence of the Janus kinase 2 V617F mutation in Philadelphia-negative myeloproliferative neoplasms in a Portuguese population. Biomed Rep. 2017 Oct;7(4):370-6. DOI: https://10.3892/br.2017.97714.

  15. Yow KS, Liu X, Chai CN, Tung ML, Yan B, Christopher D, et al. Relationship of JAK2 (V617F) Allelic Burden with Clinico- Haematological Manifestations of Philadelphia-Negative Myeloproliferative Neoplasms. Asian Pac J Cancer Prev. 2020 Sep;21(9):2805-10. DOI: https://10.31557/APJCP.2020.21.9.280515.

  16. Ha JS, Kim YK, Jung SI, Jung HR, Chung IS. Correlations between Janus Kinase 2 V617F Allele Burdens and Clinicohematologic Parameters in Myeloproliferative Neoplasms. Ann Lab Med. 2012;32(6):385-91. DOI: https://10.3343/alm.2012.32.6.38516.

  17. Palumbo GA, Stella S, Pennisi MS, Pirosa C, Fermo E, Fabris S, et al. The role of new technologies in myeloproliferative neoplasms. Front Oncol. 2019;9:321. DOI: https://10.3389/fonc.2019.0032117.

  18. Asp J, Skov V, Bellosillo B, Kristensen T, Lippert E, Dicker F, et al. International external quality assurance of JAK2 V617F quantification. Ann Hematol. 2019;98(5):1111-8. DOI: https://10.1007/s00277-018-3570-818.

  19. Vannucchi AM, Pieri L, Guglielmelli P. JAK2 allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatment. Ther Adv Hematol. 2011;2(1):21-32 DOI: https://10.1177/204062071039447419.

  20. Guglielmelli P, Pacilli A, Rotunno G, Rumi E, Rosti V, Delaini F, et al. Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood. 2017 Jun;129(24):3227-36. DOI: https://10.1182/blood-2017-01-76199920.

  21. Gángó A, Mózes R, Boha Z, Kajtár B, Timár B, Király PA, et al. Quantitative assessment of JAK2 V617F and CALR mutations in Philadelphia negative myeloproliferative neoplasms. Leuk Res. 2018 Feb;65:42-8. DOI: https://10.1016/j.leukres.2017.12.00521.

  22. Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and indepth discussion. Blood Cancer J. 2018 Feb;8(2):15. DOI: https://10.1038/s41408-018-0054-y22.




2020     |     www.medigraphic.com